Allena Pharmaceuticals, Inc. Operating Income

Operating Income of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Income growth rates and interactive chart. Operating income is the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation, and cost of goods sold (COGS). Operating income–also called income from operations–takes a company's gross income, which is equivalent to total revenue minus COGS, and subtracts all operating expenses. A business's operating expenses are costs incurred from normal operating activities and include items such as office supplies and utilities. Operating income is measured before interest and tax expenses and is a good gauge of a company's operational profitability.


Highlights and Quick Summary

  • Operating Income for the quarter ending March 31, 2022 was $-11.6 Million (a 14.19% increase compared to previous quarter)
  • Year-over-year quarterly Operating Income decreased by -15.56%
  • Annual Operating Income for 2021 was $-47.6 Million (a 48.97% increase from previous year)
  • Annual Operating Income for 2020 was $-32 Million (a -32.7% decrease from previous year)
  • Annual Operating Income for 2019 was $-47.5 Million (a 33.52% increase from previous year)
  • Twelve month Operating Income ending March 31, 2022 was $-47.8 Million (a 0.31% increase compared to previous quarter)
  • Twelve month trailing Operating Income increased by 11.15% year-over-year
Trailing Operating Income for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-47.8 Million $-47.6 Million $-47.5 Million $-43 Million
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Income of Allena Pharmaceuticals, Inc.

Most recent Operating Incomeof ALNA including historical data for past 10 years.

Interactive Chart of Operating Income of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Operating Income for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-11.56
2021 $-10.12 $-12.43 $-13.69 $-11.41 $-47.65
2020 $-9.99 $-7.92 $-6.56 $-7.52 $-31.99
2019 $-11.29 $-13.34 $-11.34 $-11.56 $-47.53
2018 $-9.78 $-9.71 $-8.14 $-7.97 $-35.59
2017 $-6.57 $-4.36 $-4.48 $-5.54 $-20.95
2016 $-6.1 $-24.19
2015 $-13.91

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.